Get the Daily Brief
Latest Biotech News
AI and Multiomics Fusion: Proteomics Integration Drives Biology Forward
Innovations in multiomics propel biology into integrative analyses combining genomics, transcriptomics, and proteomics. Collaborations between sequencing firms and proteomics companies have...
FDA Greenlights Pembrolizumab for Resectable Head and Neck Cancer
Pembrolizumab has received FDA approval for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1 (CPS ≥1), marking the first checkpoint inhibitor approved for...
23andMe Assets Acquired by Anne Wojcicki's Nonprofit Amid Bidding
Anne Wojcicki, co-founder and former CEO of 23andMe, through her nonprofit TTAM Research Institute, won a $305 million bid to acquire most of 23andMe's assets. The win overturned a prior Regeneron...
Novo Nordisk Advances Dual GLP-1, Amylin Obesity Drug to Late Trials
Novo Nordisk plans phase 3 clinical studies for amycretin, a dual GLP-1 and amylin receptor agonist, targeting overweight and obesity. Early trials showed significant weight loss with both...
Advanced CAR-T Data: J&J Sees High Response in Dual-Target Trial
Johnson & Johnson disclosed promising early data from its dual CD19/CD20-targeting CAR-T program in relapsed/refractory large B-cell lymphoma. Among patients with one prior therapy, objective...
Biotech Bill Prioritizes R&D and Patient Affordability Strategies
The US budget reconciliation bill includes pivotal biotech provisions supporting innovation and patient access. Key components involve the ORPHAN Cures Act fixing rare disease drug exemptions in...
Peripheral Nerve Fiber Research Advances Parkinson’s Diagnosis
A landmark cohort study published in npj Parkinson’s Disease reveals that pathological changes in skin-accessible cutaneous nerve fibers provide novel insights into Parkinson’s disease and...
Novo Nordisk Initiates Phase 3 Trials for Next-Gen Obesity Drug Amycretin
Novo Nordisk advances its obesity pipeline by planning late-stage clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist. Following promising phase 2 data indicating substantial...
ADC Therapeutics Cuts Workforce, Closes UK R&D Site Amid Setbacks
ADC Therapeutics announced a 30% workforce reduction and the closure of its UK R&D facility after halting development of multiple preclinical and clinical candidates due to limited efficacy and...
Magnetic Soft Millirobot Enables Simultaneous Mobility and Sensing
A research team led by W. Zeng and colleagues has developed a magnetic soft millirobot that can both navigate and sense environmental variables simultaneously. Utilizing a polymer matrix with...
Parkinson’s Disease: Novel Insights into Peripheral Nerve Fiber Changes
Recent cohort studies published in npj Parkinson’s Disease reveal key alterations in cutaneous nerve fibers in Parkinson’s disease (PD) and atypical parkinsonism. Using immunohistochemical...
FDA Approves Pembrolizumab for Locally Advanced Head and Neck Cancer
The U.S. Food and Drug Administration has approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1 (CPS ≥1). This marks the first...
23andMe Acquired by Founder’s Nonprofit After Bidding War
Anne Wojcicki, co-founder and former CEO of 23andMe, led a nonprofit, the TTAM Research Institute, which has secured a $305 million deal to acquire the majority of 23andMe’s assets after...
Novo Nordisk to Initiate Phase 3 Trials for Next-Generation Obesity Drug Amycretin
Novo Nordisk has announced plans to commence late-stage (phase 3) clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist designed for weight loss. This program includes both...
Rapid Construction of Vascular Organoids via Dual Transcription Factor Activation
Researchers from Boston Children’s Hospital and collaborators have developed an accelerated method to generate vascular organoids from human induced pluripotent stem cells (iPSCs) by...
Advanced Multiomics Partnerships Accelerate Biological Insight
Multiomics approaches integrating genomics, transcriptomics, and proteomics are increasingly central to life sciences. Ultima Genomics and partners like Olink Proteomics have collaborated to...
New Cooling Technology Promises Energy Savings for Data Centers
Engineers at the University of California San Diego have developed an evaporative cooling technology using fiber membranes with controlled porosity to passively dissipate heat from electronics....
AI Trained on Single-Cell Immune Data to Enhance Cancer Immunotherapy
Immunai has partnered with the Parker Institute for Cancer Immunotherapy to generate a large-scale, clinically annotated single-cell gene expression dataset from over 1,000 cancer patients...
AI Advances Psychiatry with Faster, Smarter Treatment Decisions
Clinical trials and real-world data increasingly harness artificial intelligence and digital biomarkers to refine psychiatric treatment strategies. AI tools offer psychiatrists improved...
FDA Approves Pembrolizumab for Resectable Head and Neck Cancer
The FDA approved pembrolizumab for resectable locally advanced head and neck cancer with PD-L1 expression, based on data from the KEYNOTE-689 phase 3 trial showing improved event-free survival and...